by Scott Miller | Oct 12, 2022
As part of a growing portfolio of biomedical HIV prevention options, long-acting injectable cabotegravir (CAB-LA) was approved by the US FDA in December 2021. Evidence from two clinical trials, HPTN 083 and HPTN 084, which enrolled nearly 8,000 participants across 13...
by Scott Miller | Sep 19, 2022
Our monthly check-in with staff from around the world. Learn more about the people who work at CHAI. Lakshmi Balachandran Senior Director, Digital Health London, UK Start date: August 2013 Sameen Babur Senior Technical Advisor, Health Informatics Washington, D.C., USA...
by Scott Miller | Sep 7, 2022
10-country partnership in Africa and Southeast Asia—to introduce COVID oral antivirals and national test-and-treat programs—announced by new public-private consortium. As Omicron subvariants continue to emerge and spread, the COVID Treatment Quick Start...
by Scott Miller | Aug 25, 2022
Four things you should know about darunavir Introduction A critical second-line HIV treatment called darunavir/ritonavir (DRV/r) is rolling out across Nigeria and Zambia – some of the earliest adopters of many countries that can now access an affordable supply of...
by Scott Miller | Aug 22, 2022
Hepatitis C (HCV) is an infectious, bloodborne virus that causes liver inflammation and can lead to liver failure and cancer. It is a silent killer, as patients do not exhibit any symptoms. Every 30 seconds, a person dies from a hepatitis-related illness; elimination...
